Articles tagged with Alzheimer Disease
Research reveals enlarged endosomes as early sign of neurodegeneration in Alzheimer's Disease and Down Syndrome. Abnormally active Rab5 protein disrupts axonal transport and neuronal function.
A study by Université Laval researchers found that a drop in body temperature associated with aging can aggravate the main manifestations of Alzheimer's disease. The study used transgenic mice to demonstrate this link and suggests that thermoregulation therapy could be a potential treatment option.
A new study reveals that a targeted immune pathway may be the key to preserving cognitive function in Alzheimer's disease. By blocking this pathway, researchers were able to reduce synapse loss in mouse models of the disease, offering hope for a potential therapeutic target to halt its progression.
Researchers at Gladstone Institutes found that increasing levels of protein tau may reverse cognitive deficits caused by Alzheimer's disease. They discovered that tau disrupts memory in models of Alzheimer's disease by depleting protein KIBRA, which is critical for memory formation.
Researchers found that mimicking simple actions can aid recovery, with human trainers outperforming computer-based methods. The study suggests a potential tool for rehabilitation, providing insight into the ongoing ability of Alzheimer's patients to imitate movements.
A recent study by University of Edinburgh researchers has identified two genetic variants that can cut a person's lifespan by up to three years. The variants, which are relatively common in the population, have been linked to an increased risk of lung cancer and severe respiratory problems as well as Alzheimer
A study found that increased arterial stiffness in young adults is associated with reduced white matter volume and decreased gray matter integrity. This association suggests that vascular health can impact brain health from an early age.
EPFL scientists have created an implantable capsule that can deliver antibodies to target and clear amyloid beta protein plaques in the brain, potentially treating Alzheimer's disease. The device has been tested on mice with great success, reducing Abeta plaque load and phosphorylation of tau protein.
Researchers used optogenetics to re-grow lost spines and restore memories in AD mice by stimulating engram cells. This method suggests that impaired retrieval of memories underlies early Alzheimer's disease symptoms and highlights the importance of targeted manipulation of neurons for future therapies.
A study by MIT neuroscientists suggests that early-stage Alzheimer's patients can form new memories but struggle to recall them. The researchers used optogenetics to stimulate the cells holding these memories and were able to retrieve them in mice with Alzheimer's symptoms.
Researchers found that pyruvate increases brain energy reserves and improves cognitive function in mice, including enhanced exploratory behavior and spatial learning. The findings suggest potential therapeutic applications for Alzheimer's disease and other neurodegenerative disorders.
A study published by the American Academy of Neurology found that women tend to perform better on verbal memory tests and have less brain shrinkage in areas responsible for verbal memory. This suggests that women may be protected from loss of verbal memory skills before Alzheimer's disease symptoms appear.
Researchers at UT Southwestern Medical Center found a link between traumatic brain injury and mild cognitive impairment, with those who experienced loss of consciousness for over five minutes being at greater risk. The study analyzed data from 3,187 people diagnosed with mild cognitive impairment versus a normal-cognition group of 3,244.
The novel blood test detects misfolded Amyloid beta peptides in body fluids, revealing potential for early detection of Alzheimer's. The test has achieved high diagnostic precision with a sensitivity of up to 90% and is being further optimized in ongoing studies.
Research suggests that a pure maple syrup extract may help prevent the misfolding and clumping of brain proteins associated with Alzheimer's disease. The extract also showed neuroprotective effects in rodent microglial brain cells, potentially benefiting neurological health.
A comprehensive report by internationally leading researchers calls for concerted efforts to reduce the burden of dementia. The report advocates for public governmental agencies to form large multinational partnerships with academic centers and pharmaceutical companies to deploy capital resources and share risk.
New research suggests blueberries could have a real benefit in improving memory and cognitive function in some older adults. The fruit's flavonoids, particularly anthocyanins, may improve animals' cognition and have anti-inflammatory effects on the brain.
A new study found that physically active older adults have larger gray matter volumes in key brain areas, which can help prevent cognitive decline. People with high calorie burn are more likely to develop Alzheimer's disease or experience less volume reduction over time.
A new study has found a strong link between gum disease and increased rates of cognitive decline in people with early stages of Alzheimer's Disease. Periodontitis at baseline was associated with a six-fold increase in the rate of cognitive decline over a six-month follow-up period.
A European-funded study found that a nutritional drink can help conserve memory and reduce brain shrinkage in people with prodromal Alzheimer's disease. While the primary endpoint was not met, significant differences were observed for hippocampal and whole-brain atrophy, as well as improvements in CDR Sum of Boxes and episodic memory.
Researchers at UCL have made significant discoveries about the brain's role in imagination and navigation. Grid cell activity has been observed in healthy volunteers imagining moving through an environment, suggesting a potential link between grid cells and Alzheimer's disease.
A new review proposes using cheap and quick point-of-care tests to measure beta-amyloid levels in the blood, enabling doctors to deliver personalized care and improving patients' quality of life. The tests could be especially beneficial for patients in developing countries where access to healthcare is limited.
A protein critical to brain waste removal, TREM2, is diminished in age-related macular degeneration (AMD) and Alzheimer's disease. The research identified a key reason, microRNA-34a, leading to a new treatment target for both conditions.
Researchers have discovered that amyloid protein build-up is greater on the left side of the brain, where language processing occurs, in individuals with primary progressive aphasia (PPA). This study provides new insights into the disease process and offers hope for early diagnosis and treatment.
A new study from Lund University reveals that the accumulation of amyloid beta in the brain may be caused by both overproduction and problems with breaking down the protein. The research suggests that Alzheimer's disease may be a more heterogeneous condition than previously thought, with potential implications for future treatments.
A recent study from the University of Eastern Finland found that antidepressant use begins years before an Alzheimer's disease diagnosis. The most common antidepressants prescribed were selective serotonin reuptake inhibitors (SSRIs) and mirtazapine.
A key brain receptor has been found to both strengthen and weaken synapses, offering new insights into mechanisms driving depression, drug addiction, and Alzheimer
Researchers have identified a new biomarker associated with the activation of an innate immune response to neural damage during early stages of Alzheimer's disease. The concentration of a specific segment of the protein TREM2 in cerebrospinal fluid is significantly elevated in early stages of the disease.
A new biomarker of brain inflammation in early-stage Alzheimer's disease has been identified, indicating that microglia-mediated inflammation may demarcate the transition from preclinical to full dementia. The TREM2 protein fragment in cerebrospinal fluid levels closely mirror microglia activity during the course of the disease.
Researchers used PET scans to study the progressive stages of Alzheimer's disease in cognitively normal adults, tracking tau protein accumulation in the brain. The findings suggest that tau imaging could become an important tool in developing therapeutic approaches targeting either amyloid or tau, depending on the disease stage.
Researchers present innovative approaches using cell transplantation and genetic engineering to address neurodegenerative diseases, including Alzheimer's and Huntington's. Studies show promise in reducing learning deficits and alleviating peripheral neuropathic pain, offering new hope for treatment options.
A study using molecular simulations suggests that polyunsaturated lipids can alter the binding rate of dopamine and adenosine receptors, affecting cell function in neurodegenerative diseases. This discovery could lead to new therapeutic pathways for regulating receptor binding.
A five-year $1-million grant aims to teach people how to protect their brains through exercise, with a focus on African-Americans at elevated dementia risk. The program will include dance-based exercise and lifestyle education, and gather data on brain circuitry, aging, and stress levels.
Researchers found that flushing away inflammatory cells contributed to restored memory function in test mice with Alzheimer's disease. The study suggests targeting these cells with specific drugs may be a promising new approach.
A breakthrough study sponsored by the Office of Naval Research (ONR) Global has significantly boosted the memory and mental performance of laboratory mice through Transcranial Direct Current Stimulation (tDCS). The researchers observed improved performance in navigating a water maze and distinguishing between known and unknown objects,...
A novel therapeutic approach has been developed to target the monomeric Tau protein, reducing its misfolding and aggregation that leads to Alzheimer's and other neurodegenerative diseases. The study identified small molecule drug candidates capable of maintaining native function and preventing disease onset.
A Phase 2 study demonstrated the safety of deep brain stimulation (DBS) in treating mild Alzheimer's disease. No adverse effects were reported, but the next step is evaluating efficacy and longer-term safety in a larger patient population.
Scientists have discovered a way to specifically target and inhibit the most harmful behavior of the amyloid precursor protein in Alzheimer's disease. This new therapeutic strategy could potentially treat AD without causing major side effects.
Researchers from the Center for Nanoparticle Research design a novel therapeutic agent capable of impeding neuronal cell death associated with Alzheimer's disease. The treatment targets mitochondrial dysfunction and oxidative stress, offering new hope for treating this debilitating neurodegenerative disorder.
Researchers have developed a targeted substance that blocks the pathogenic function of an Alzheimer's enzyme in cells, reducing toxic β amyloid peptide production. This selective inhibition may lead to effective treatment without severe side effects, offering hope for Alzheimer's patients.
A recent study found that mental activity may help delay the onset of Alzheimer's symptoms, but it does not affect the underlying disease changes in the brain. For carriers of the APOE4 gene, continued lifetime learning was associated with lower levels of amyloid plaques.
A recent study published in Neurology found that maintaining mental activity can slow the onset of Alzheimer's symptoms in people without a family history of the disease. For those with the APOE4 gene, continued learning and intellectual activity in middle age can lower amyloid plaque levels.
Researchers found a dramatic increase in brain plaques when key immune cells are lacking in genetically modified mice, leading to new techniques to identify and treat individuals at risk of developing Alzheimer's. The study suggests the immune system plays a crucial role in clearing beta-amyloid from the brain.
Researchers have identified multiple gene therapy approaches to treat Alzheimer's disease, including boosting neuroprotection, increasing autophagy-related proteins, and regulating lipid metabolism. These strategies aim to address the underlying neuropathological changes associated with the disease.
Researchers at Uppsala University have developed a new PET imaging method that uses monoclonal antibodies to provide more precise information on the brain than traditional radioactive tracers. The method has shown high specificity and can monitor the progression of Alzheimer's disease, allowing for better assessment of medication effects.
The locus coeruleus is a critical brain region that releases norepinephrine, regulating heart rate, attention, memory, and cognition. It is vulnerable to toxins and infection, making it the first place affected by late-onset Alzheimer's disease.
Researchers at Mayo Clinic have discovered that apraxia of speech can evolve into a neurodegenerative disease, causing significant difficulties with speech, movement, and daily activities. Early diagnosis and therapy are crucial to develop compensations for producing sounds and improving communication.
A new drug called bexarotene has been identified as a potential 'neurostatin' that targets the first step in the toxic chain reaction leading to brain cell death. This delay can prevent Alzheimer's symptoms from appearing, suggesting a new avenue for treatments.
Researchers at Tel Aviv University have discovered a novel peptide that enhances memory and reveals significant gender differences in the brain. The peptide, developed to treat neuroprotective protein deficiencies, has been shown to accelerate microtubular function and normalize nerve-cell transport in both males and females.
A new study based on the Framingham Heart Study data reveals a progressive decline in dementia incidence over nearly 40 years, with a 20% reduction per decade since the 1970s. The decline was more pronounced in persons with high school education and above, suggesting the importance of effective prevention strategies.
Researchers have devised several lipid-based diets aimed at slowing down progression and relieving symptoms of Alzheimer's disease. These diets, such as the Fortasyn diet enriched with fish oil, have been shown to increase density of muscarinic receptors and cholinergic synapses in the hippocampus.
Researchers found a disordered mesh-like scaffold in Alzheimer's-affected cells, which surrounds the nucleus and controls brain cell function. This discovery may lead to new treatments for the earliest biological events leading to Alzheimer's disease.
A recent study published in Neurology has revealed that protein clumps associated with Alzheimer's disease are found in the brains of people who have had a head injury. These clumps, called amyloid plaques, were found to be present in patients over a decade after the injury.
A new study found increased buildup of amyloid plaques in people who had previously sustained a traumatic brain injury. The areas affected overlapped those seen in Alzheimer's disease, but other areas were involved.
A study of deceased individuals found that moderate seafood consumption was correlated with lesser Alzheimer disease neuropathology, despite higher brain levels of mercury. The study suggests that selenium, an essential nutrient in seafood, may reduce mercury toxicity and its negative effects on the brain.
Research suggests that eating at least one seafood serving per week may lower the risk of developing Alzheimer's disease in older adults with the APOE-4 gene. The study found no association between seafood consumption and increased brain mercury levels or beta amyloid protein plaques, key markers of the disease.
A Tel Aviv University study finds IGF-1R plays a vital role in regulating hippocampal neural circuits and processing information. The research suggests that IGF-1R small inhibitors may be a potential direction for therapy to treat early-stage Alzheimer's disease.
Researchers found that an FDA-approved blood pressure drug reduced cell damage linked to Alzheimer's disease. The study supports the potential effect of other Angiotensin receptor blockers (ARBs) for early treatment.
Researchers have pinpointed cell types responsible for common brain diseases, including Alzheimer's and Multiple Sclerosis. The findings suggest that developing medicines targeting microglial cells could offer hope for treating these conditions.
A recent study found Aβ plaques in brains of recipients with Creutzfeldt-Jakob disease, sparking concerns over transmissible Alzheimer's disease. The discovery highlights the potential risks of transplantation medicine and calls for heightened attention to this issue.